NowoTrade

RGC

RGC Regencell Bioscience Holdings Limited

Stock · NasdaqCM · Hong Kong · Healthcare · KYG7487R1002

NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Regencell Bioscience Holdings Limited, and has no access to any account you may have with it. The name and the logo belong to their owners.

Price 5.27 USD 0.00%
52-week range 4.51 – 69.00
Dividend yield—
Market cap2.6B
NowoTrade score 18 Grade C

Price history

Daily prices in USD.

Updated 08 Nov 2026 14:26. Information, not advice.

Results

Next results 06 May 2027 in 179 days · 17:00
Last results —Nothing reported yet
Beat the estimate — 
Average surprise — reported against the estimate, last 0 quarters

Quarterly results

DateEPS estimateEPS reportedSurpriseResult
06 May 2027 17:00 — — — Upcoming
28 Oct 2026 16:00 — — — —
15 Jun 2026 16:00 — — — —
18 Nov 2025 16:00 — — — —
16 Jul 2025 16:00 — — — —

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2026 0 — -11.7M — — — -7.7M
2025 — — — — -0.01 +17.2% —
2024 0 — -4.3M — -0.01 +26.9% -4M
2023 0 — -5.9M — -0.01 +22.0% -5M
2022 0 — -7.4M — -0.02 — -6M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Price history in USD, by day
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
24 Jul 2025 14.88 15.37 14.56 15.18 +2.64% 525,300
23 Jul 2025 13.75 18.41 13.75 14.79 +8.19% 2,758,200
22 Jul 2025 14.29 14.29 13.51 13.67 -5.07% 407,400
21 Jul 2025 14.00 14.40 13.65 14.40 -0.69% 504,200
18 Jul 2025 15.60 15.60 14.15 14.50 -2.42% 644,400
17 Jul 2025 16.64 16.68 14.33 14.86 -2.81% 1,055,600
16 Jul 2025 14.50 15.30 14.05 15.29 +11.61% 1,352,500
15 Jul 2025 14.18 15.15 13.67 13.70 -6.68% 813,600
14 Jul 2025 14.30 15.84 13.54 14.68 -0.47% 1,074,400
11 Jul 2025 16.10 16.31 13.92 14.75 -10.96% 1,274,800
10 Jul 2025 17.05 18.83 16.27 16.57 -4.80% 1,060,800
09 Jul 2025 19.52 19.71 16.80 17.40 -9.89% 1,451,300
08 Jul 2025 20.93 21.30 18.80 19.31 +4.77% 2,594,900
07 Jul 2025 25.10 30.00 18.20 18.43 -19.83% 5,696,000
03 Jul 2025 11.00 28.00 10.91 22.99 +121.91% 18,796,200
02 Jul 2025 14.00 14.12 9.39 10.36 -29.04% 1,684,000
01 Jul 2025 15.70 16.42 14.47 14.60 -14.32% 493,500
30 Jun 2025 16.67 17.85 15.11 17.04 -2.07% 803,200
27 Jun 2025 19.80 19.96 15.60 17.40 -13.82% 986,600
26 Jun 2025 20.20 22.92 19.21 20.19 -7.09% 987,100
25 Jun 2025 25.79 26.00 17.00 21.73 -5.32% 2,064,000
24 Jun 2025 22.64 34.58 21.69 22.95 -3.16% 2,536,400
23 Jun 2025 30.00 31.53 19.80 23.70 -37.65% 1,857,900
20 Jun 2025 54.60 58.71 32.13 38.01 -40.00% 2,219,000
18 Jun 2025 60.01 67.66 53.01 63.35 -18.78% 1,788,200

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close
5.27 USD
Market cap
2.6B
Exchange
NasdaqCM
Country
Hong Kong
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 8.8 / 25 No figures for this part: it counts as a cautious 35%. —
Quality Return on equity, net margin and how stable the margins are. 0.0 / 25
  • ROE of -129%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 9.6 / 20
  • Free cash flow yield of -0.1%
Valuation Free cash flow yield and the P/E against its sector. 0.0 / 15 —
Analysts How far the analysts' average target is from today's price. 3.5 / 10 No figures for this part: it counts as a cautious 35%. —
  • Score capped at 60: free cash flow was negative in two of the last three years
  • The last full year was a loss

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 60% of the figures (grade C). Warnings take 6 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.

Figures

Valuation
FigureValueReading Sector median
Price / book 195.19× Weak 3.8×
EV / EBITDA -223.25× Weak 12.61×
Free cash flow yield -0.1% Weak 2.5%
Quality
FigureValueReading Sector median
Gross margin 0% Weak 58.6%
Operating margin 0% Weak 7.6%
Net margin 0% Weak 2.7%
Return on equity -128.5% Weak 5.7%
Return on assets -71.5% Weak 3.5%
Financial health
FigureValueReading Sector median
Debt / equity 0.02× Good 0.48×
Current ratio 10.77× Good 2.36×

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Follow RGC and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in